The effects of high concentrations of vitamin C on cancer cells

Nutrients

Volumn 5, Issue 9, 2013, Pages 3496-3505

  Park, Seyeon ^a  

^a Dongduk Women's University   (South Korea)

Author keywords

High concentrations of vitamin C; Pharmacogenomics; Pharmacoproteomics

Indexed keywords

ASCORBIC ACID; CYSTEINE; ERLOTINIB; GEMCITABINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE TRANSFERASE; PACLITAXEL; PROTEIN DISULFIDE ISOMERASE; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CORNEA NEOVASCULARIZATION; DRUG BLOOD LEVEL; DRUG POTENTIATION; FATIGUE; GLIOBLASTOMA; HUMAN; IC 50; LETHARGY; LEUKEMIA CELL; MIGRATION INHIBITION; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVARY TUMOR; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS TUMOR; PHARMACOGENOMICS; PROTEOMICS; REVIEW; SARCOMA 180; SURVIVAL RATE;

ANIMALS; ASCORBIC ACID; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HUMANS; NEOPLASMS; PHARMACOGENETICS; PROTEOMICS;

EID: 84884180333     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu5093496     Document Type: Review

References (49)

1. Bram, S.; Froussard, P.; Guichard, M.; Jasmin, C; Auqery, Y.; Sinoussi-Barre, F.; Wray, W. Ascorbic acid preferential toxicity for malignant melanoma cells. Nature 1980, 284, 629-631.
2. Bruchelt, G.; Baader, L.; Reith, A.G.; Holger, N.L.; Gebhardt, S.; Niethammer, D. Rationale for the Use of Ascorbic Acid in Neuroblastoma Therapy. In Human Neuroblastoma; Schwab, M., Ed.; Harwood Academic Publishers: Newark, NJ, USA, 1993; pp. 34-40.
3. Fujinaga, S.; Sakagami, H.; Kuribayashi, N.; Takahashi, H.; Amano, Y.; Sakagami, T.; Takeda, M. Possible role of hydrogen peroxide in apoptosis induction by ascorbic acid in human myelogenous leukemic cell lines. Showa Univ. Med. Sei. 1994, 6, 135-144.
4. De Laurenzi, V.; Melino, G.; Savini, I; Annicchiarico-Petruzzelli, M.; Finazzi-Agro, A.; Avigliano, L. Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. Eur. J. Cancer 1995, 31, 463-466.
5. Park, C.H.; Bergsagel, D.E.; McCulloch, E.A. Ascorbic acid: A culture requirement for colony formation by mouse plasmacytoma cells. Science 1971, 174, 720-722.
6. Park, C.H. The biological nature of the effect of ascorbic acids on the growth of human leukemic cells. Cancer Res. 1985, 45, 3969-3973.
7. Park, C.H.; Kimler, B.F.; Bodensteiner, D.; Lynch, S.R.; Hassanein, R.S. In vitro growth modulation by L-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes. Cancer Res. 1992, 52, 4458-4466.
8. Sakagami, H.; Asano, K.; Fukuchi, K.; Gomi, K.; Ota, H.; Kazama, K.; Tanuma, S.; Kochi, M. Induction of tumor degeneration by sodium benzylideneascorbate. Anticancer Res. 1991, 11, 1533-1538.
9. Park, C.H.; Kim, W.S.; Park, C; Lee, M.H.; Boo, Y.C.; Yoon, S.S. Clinical disease suppression and reduction in acute myeloid leukemia and solid tumors by very high dose of L-ascorbic acid: A new concept and in search of molecular targets. Clin. Cancer Res. 1999, 5, 3784s.
10. Padayatty, S.J.; Sun, H.; Wang, Y; Riordan, H.D.; Hewitt, S.M.; Katz, A.; Wesley, R.A.; Levine, M. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Ann. Intern. Med. 2004, 140, 533-537.
11. Levine, M.; Conry-Cantilena, C; Wang, Y; Welch, R.W.; Washko, P.W.; Dhariwal, K.R.; Park, J.B.; Lazarev, A.; Graumlich, J.; King J. et al. Vitamin C Pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc. Natl. Acad. Sei. USA 1996, 93, 3704-3709.
12. Levine, M.; Wang, Y; Padayatty, S.J.; Morrow, J.D. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sei. USA 2001, 98, 9842-9846.
13. Chen, Q.; Espey, M.G.; Cherukuri, M.K.; Mitchell, J.B.; Corpe, C.P; Buettner, G.R.; Shacter, E.; Levine, M. Ascorbic acid at Pharmacologic concentrations selectively kill cancer cells: Ascorbic acid as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sei. USA 2005, 102, 13604-13609.
14. Levine, M.; Rumsey, S.C.; Daruwala, R.C.; Park, J.B.; Wang, Y. Criteria and recommendation for vitamin C intake. J. Am. Med. 1999, 281, 1415-1423.
15. Riordan, N.H.; Riordan, H.D.; Casciari, J.J. Clinicla and experimental experiences with intravenous vitamin C. J. Orthomol. Med. 2000, 15, 201-203.
16. Riordan, H.D.; Hunninghake, R.E.; Riordan, N.H.; Jackson, J.J.; Meng, X.; Taylor, P.; Casciari, J.J.; Gonzalez, M.J.; Miranda-Massari, J.R.; Mora, E.M. et al. Intravenous Ascorbic Acid: Protocol for its Application and Use. P. R. Health Sei. J. 2003, 22, 287-290.
17. Park, S.; Han, S.S.; Park, C.H.; Hahm, ER.; Lee, S.J.; Park, H.K.; Lee, S.H.; Kim, WS.; Jung, C.W.; Park, K.; et al. L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. Int. J. Biochem. CellBiol. 2004, 36, 2180-2195.
18. Park, S. Samsung Medical Center, Seoul, Korea. Unpublished work, 2004.
19. Park, S.; Lee, J.; Yeom, C.H. A proteomic approach to the identification of early molecular targets changed by L-ascorbic acid in NB4 human leukemia cells. J. Cell. Biochem. 2006, 99, 1628-1641.
20. Bienert, G.P; Schjoerring, J.K.; Jahn, T.P. Membrane transport of hydrogen peroxide. Biochim. Biophys. Acta 2006, 1758, 994-1003.
21. Seaver, L.C.; Imlay, A.J. Hydrogen peroxide fluxes and compartmentalization inside growing Escherichiacoli. J. Bacteriol. 2001, 183, 7182-7189.
22. 2 gradients across biomembranes. FEBS Lett. 2000, 475, 121-126.
23. 2 permeation through cytoplasmatic and peroxisomal membranes: comparison with experimental data. Biochim. Biophys. Acta 2004, 1673, 149-159.
24. 2 protects Saccharomyces cerevisiaein stationary phase against oxidative stress. FEBS Lett. 2004, 578, 152-156.
25. Mathai, J.C; Sitaramam, V. Střech sensitivity of transmembrane mobility of hydrogen peroxide through voids in the bilayer. J. Biol. Chem. 1994, 269, 17784-17793.
26. Zhu, X.H.; Shen, Y.L.; Jing, Y.K.; Cai, X.; Jia, P.M.; Huang, Y; Tang, W.; Shi, G.Y; Sun, YP; Dai, J. et al. Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations. J. Natl. Cancer Inst. 1999, 91, 772-778.
27. Dai, J.; Weinberg, R.S.; Waxman, S.; Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999, 93, 268-277.
28. Noiva, R. Protein disulfide isomerase: The multifunctional redox chaperone of the endoplasmic reticulum. Semin. Cell Dev. Biol. 1999, 10, 481-493.
29. Kemmink, J.; Darby, N.J.; Dijkstra, K.; Nilges, M.; Creighton, T.E. The folding catalyst protein disulfide isomerase is constructed of active and inactive thioredoxin modules. Curr. Biol. 1997, 7, 239-245.
30. Park, S. Apoptosis of Leukemia Cells Induced by L-Ascorbic Acid and Arsenic Trioxide: The Effect of Oxidative Stress and Glutathione homeostasis.Albina. In Cell Apoptosis and Cancer; Taylor, A.W., Ed.; Nova Science Publishers, Inc.: New York, NY, USA, 2007; pp. 87-111.
31. John, D.C.; Bulleid, N.J. Intracellular dissociation and reassembly of prolyl 4-hydroxylase: The alpha-subunits associated with the immunoglobulin-heavy-chain binding protein (BiP) allowing reassembly with the β-subunit. Biochem. J. 1996, 317, 659-665.
32. Houle, E; Rousseau, S.; Monice, N.; Luc, M.; Mongrain, S.; Turner, C.E.; Tanaka, S.; Moreau, P.; Huot, J. Extracellular signal-regulated kinase mediates phosphorylation of tropomyosin-1 to promote cytoskeleton remodeling in response to oxidative stress: impact on membrane blebbing. Mol. Biol. Cell 2003, 14, 1418-1432.
33. Zou, L.; Wu, Y; Pei, L.; Zhong, D.; Gen, M.; Zhao, T.; Wu, J.; Ni, B.; Mou, Z.; Han, J. et al. Identification of leukemia-associated antigens in chronic myelcoid leukemia by proteomic analysis. Leuk. Res. 2005, 29, 1387-1391.
34. Chen, Q.; Espey, M.G.; Sun, A.Y; Lee, J.H.; Krishna, M.C.; Shacter, E.; Choyke, PL.; Pooput, C; Kirk, K.L.; Buettner, G.R.; et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sei. USA 2007, 104, 8749-8754.
35. Chen, Q.; Espey, M.G; Sun, A.Y; Pooput, C; Kirk, K.L.; Krishna, M.C.; Khosh, D.B.; Drisko, J.; Levin, M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sei. USA 2008, 105, 11105-11109.
36. Mikirova, N.A.; Ichim, T.E.; Riordan, N.H. Anti-angiogenic effect ofhigh doses of ascorbic acid. J. Transl. Med. 2008, 6, doi:10.1186/1479-5876-6-50.
37. Peyman, G.A.; Kivilcim, M.; Morales, A.M.; DellaCroce, J.T.; Conway, M.D. Inhibition of corneal angiogenesis by ascorbic acid in the ratmodel. Graefe's Arch. Clin. Exp. Ophthalmol. 2007, 245, 1461-1467.
38. Yeom, C.H.; Lee, G; Park, J.; Yu, J.; Park, S.; Yi, S.Y; Lee, H.; Hong, Y; Yang, J.; Lee, S. High dose concentration administration of ascorbic acid inhibits tumor growth in BLAB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J. Transl. Med. 2009, 7, doi:10.1186/1479-5876-7-70
39. Park, S.; Ahn, E.S.; Lee, S.; Jung, M.; Park, J.H.; Yi, S.Y.; Yeom, C.H. Proteomicanalysis reveals upregulation of RKIP in S-180 implanted BALB/C mouse after treatment with ascorbic acid. J. Cell. Biochem. 2009, 106, 1136-1145.
40. Park, J.H.; Davis, K.R.; Lee, G.; Jung, M.; Jung, Y; Park, J.; Yi, S.Y; Lee, M.A.; Lee, S.; Yeom, C.H.; et al. Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. Nutr. Res. 2012, 32, 873-883.
41. Padayatty, S.J.; Riordan, H.D.; Hewitt, S.M.; Katz, A.; Hoffer, L.J.; Levine, M. Intravenously administered vitamin C as cancer therapy: Three cases. CMAJ 2006, 174, 937-942.
42. Riordan, H.D.; Jackson, J.A.; Riordan, N.H.; Schultz, M. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J. Orthomol. Med. 1998, 13, 72-73.
43. Riordan, H.D.; Riordan, N.H.; Jackson, J.A.; Casciari, J.J.; Hunninghake, R.; Gonzalez, M.J.; Mora, E.M.; Miranda-Massari, J.R.; Rosario, N.; Rivera, A. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P. R Health Sei. J. 2004, 23, 115-118.
44. Riordan, H.D.; Jackson, J.A.; Schultz, M. Case study: High-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney. J. Orthomol. Med. 1990, 5, 5-7.
45. Jackson, J.A.; Riordan, H.D.; Hunninghake, R.E.; Riordan, N. High-dose intravenous vitamin C and long-time survival of a patient with cancer of the head of the pancreas. J. Orthomol. Med. 1995, 10, 87-88.
46. Riordan, N.H.; Jackson, J.A.; Riordan, H.D. Intravenous vitamin C in a terminal cancer patient. J. Orthomol. Med. 1996, 11, 80-82.
47. Padayatty, S.J.; Sun, A.Y; Chen, Q.; Espey, M.G.; Drislo, J.; Levine, M. Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010, 5, ell411.
48. Monti, D.A.; Mitchell, E.; Bazzan, A.J.; Liftman, S.; Zabrecky, G.; Yeo, C.J.; Pillai, M.V.; Newberg, A.B.; Deshmukh, S.; Levine, M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012, 7, e29794.
49. Park, C.H.; Kimler, B.E; Yi, S.Y; Park, S.H.; Kim, K.; Jung, C.W.; Kim, S.H.; Lee, E.R.; Rha, M.; Kim, S. et al. Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. Eur. J. Haematol. 2009, 83, 108-118.